There is a need for compositions and methods for treating nervous system disorders, such as by inducing remyelination and neuroprotection. In this context, the present invention relates to use of a RXR agonist in the manufacture of a medicament for the treatment of a nervous system disorder in an individual, wherein the medicament is adapted for administration with a thyroid hormone selected from thyroxine and triiodothyronine, wherein the selective RXR agonist is 3,7-dimethyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, bexarotene, or LG268, and wherein the combination of RXR agonist and thyroid hormone causes a greater improvement in the nervous system disorder than the selective RXR agonist or thyroid hormone alone.
